HENDERSON MICHAEL THOMAS 4

What Happened

• Michael T. Henderson, a director of Spyre Therapeutics (SYRE), sold a total of 80,000 shares in open-market transactions on May 8, 2026, generating aggregate gross proceeds of about $5,952,050.
  • 2,404 shares @ $72.57 = $174,458 (prices in this lot ranged $72.03–$73.00)
  • 33,513 shares @ $73.72 = $2,470,578 (prices in this lot ranged $73.15–$74.14)
  • 24,814 shares @ $74.76 = $1,855,095 (prices in this lot ranged $74.15–$75.14)
  • 19,269 shares @ $75.35 = $1,451,919 (prices in this lot ranged $75.15–$75.71)
• These were sales (S), not purchases; the filing identifies the trades as executed under a Rule 10b5-1 trading plan adopted February 6, 2026.

Key Details

• Transaction date: 2026-05-08 (all lots); reported on Form 4 with weighted-average prices and provided price ranges per lot.
• Total shares sold: 80,000; total gross proceeds: ~$5.95 million.
• Post-transaction share ownership: Not specified in the provided filing excerpt.
• Notable footnotes: trades reported as executed pursuant to a Rule 10b5-1 plan (Feb 6, 2026); the filing supplies weighted-average prices and states the reporting person will provide detailed per-price breakdowns to the issuer, shareholders, or SEC staff upon request.
• Filing timeliness: The filing date matches the transaction date in the excerpt; no late-filing flag was provided.

Context

• Sales under a Rule 10b5-1 plan are pre-arranged trading plans that allow insiders to sell shares at scheduled times; such sales are typically routine rather than an immediate signal of insider sentiment. Retail investors should note the transaction type (sale) and the plan disclosure but avoid inferring motives from the sale alone.
• Purchases generally carry more direct informational weight than sales. If you track insider activity, watch for patterns over time (repeated large sales or new purchases) and check subsequent filings for updated ownership information.